A relatively new and promising tool in the fight against breast cancer, 3-D mammograms, also known as tomosynthesis, now will be covered by health insurance, under a policy change by the Wolf administration.
At Monday’s meeting of the Pennsylvania Breast Cancer Coalition in Harrisburg, Frances Wolf, wife of Gov. Tom Wolf, announced that 3-D mammograms are now covered by insurance under existing Pennsylvania law and must be offered to Pennsylvania women. Before the policy change, women were being prescribed the screenings, only to find they had to pay for them.
The 3-D technology was approved for use by the Food and Drug Administration in February 2011, and Magee-Womens Hospital of UPMC began using it in September of that year.
Surgeon Thomas Julian, division director for breast surgical oncology for Allegheny Health Network, said the expanded coverage, referred to as a clarification by a state Insurance Department spokesman, is a positive step.
“For women at large who are at breast cancer risk, this is absolutely an advancement and opportunity for them,” he said. “It will give them access to advanced technology for breast cancer detection. The cancer can be found at an earlier stage and treated in much more effective fashion, possibly with less treatment.”
He said among those helped are women with extremely dense breast tissue, who sometimes have follow-up screenings because cancerous tissue may lie hidden in 2-D screenings. Two other groups that would benefit are women who have already had breast cancer treatment (3-D imaging can differentiate between cancer and tissue changed from surgery or radiation) and women at extremely high risk — whether from a strong family history or genetic factors.
Read More
“We’re offering it to everybody,” said William Poller, director of breast imaging for Allegheny Health Network, who added that even women with fatty or scattered areas of density benefit from the method. The area’s largest hospital systems, UPMC and Allegheny Health, offer 3-D screening. Dr. Poller said that by the end of the year Allegheny Health plans to offer tomosynthesis at every screening site.
One of Dr. Poller’s patients, Patty Robich, 53, of Franklin Park, had the 3-D mammography earlier this year and saw the difference herself.
She doesn’t have breast cancer, but she does have dense breasts, and she and her three sisters have been called back for follow-ups after the standard 2-D method.
Getting the 3-D screen involved a procedure similar to the 2-D, she said. “If you didn’t know any better, you wouldn’t know it.”
This year, she had both types of screening and was able to see the images side by side.
“Everything was identical, but there was a huge difference in what you could see,” she said, adding that the 2-D image was obscured with what she said “almost looked like cobwebs.”
Dr. Julian said there is slightly more radiation in the 3-D mammogram, so “one has to start weighing risk and benefit. Women who have breasts that are totally fat tissue could be candidates for standard 2-D mammography and not be put at risk.”
“This is the concern of insurance carriers: Who are the best patients who really need this? Who are the patients just as well served with standard mammograms? Those are some of the nuances that will have to be looked at.”
The area’s largest health care insurers responded to Monday’s directive from the governor.
UPMC Health Plan’s vice president of medical affairs, Stephen E. Perkins, said his company “supports this expanded coverage requirement and will continue to support research not only into 3-D tomosynthesis but also into a wide range of services designed to assist women to be as healthy as they can be.”
Highmark spokesman Aaron Billger said it will “work to comply” with the order to cover 3-D mammograms. “We’re looking at a mid-October effective date where Highmark will cover 3-D tomosynthesis as a screening and diagnostic tool.”
He added that providers will be required to educate their patients on treatment options, particularly to understand the higher radiation exposure with the 3-D method. Highmark also supports additional clinical trials on breast cancer screening, he said.
Jill Daly: jdaly@post-gazette.com or 412-263-1596.




Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.